1.Effects of Forsythia suspensa ethanol extract on the proliferation,migration and invasion of lung cancer cells NCI-H226
Yulong HUANG ; Xuewu CHEN ; Fangting WANG ; Jing ZHANG ; Aiying CHEN
China Pharmacy 2023;34(15):1821-1825
OBJECTIVE To investigate the effects of Forsythia suspensa ethanol extract on the proliferation, migration and invasion of lung cancer cells NCI-H226. METHODS As research objects, lung cancer cells NCI-H226 were divided into control group, F. suspensa ethanol extract low-, medium- and high-concentration groups (5, 10, 20 mg/mL), activator group [10 mg/mL F. suspensa ethanol extract+0.5 μmol/L nuclear factor kappa B (NF-κB) signaling pathway activator PMA], inhibitor group (10 mg/mL F. suspensa ethanol extract+10 μmol/L NF-κB signaling pathway inhibitor BAY 11-7082) and positive control group (20 μg/mL cisplatin). Except for the control group of cells without intervention, all other groups of cells were cultured with corresponding drugs for 24 hours; the proliferation, migration and invasion of cells were all detected, and the proliferation rate, migration rate, and the number of invading cells were also calculated; protein expressions of NF-κB p65, NF-κB inhibitory protein α (IκBα), phosphorylated NF-κB p65 (p-NF-κB p65) and phosphorylated IκBα (p-IκBα) were determined. RESULTS Compared with control group, the proliferation rate, migration rate, and the number of invading cells as well as the protein expressions of p- IκBα and p-NF-κB p65 were decreased significantly in F. suspensa ethanol extract groups and positive control group (P<0.05). Compared with F. suspensa ethanol extract medium-concentration group, the proliferation rate, migration rate, and the number of invading cells as well as above protein expressions were all decreased significantly in inhibitor group (P<0.05), while those of activator group were increased significantly (P<0.05). CONCLUSIONS F. suspensa ethanol extract can inhibit the proliferation, migration and invasion of lung cancer cells NCI-H226, and the mechanism of which may be related to the inhibition of NF-κB signaling pathway.
2.Research progress in Filifactor alocis interacting with periodontitis
Fangting HUANG ; Biao REN ; Jiyao LI
Chinese Journal of Stomatology 2021;56(10):1034-1039
Many new microbial species which are correlated with periodontitis have been identified in addition to the"red complex"cultured by conventional methods due to the development of high-throughput sequencing technology. Filifactor alocis (Fa), as a anaerobic Gram-positive bacteria, is closely related to the occurrence and development of periodontitis. Fa can not only destroy host cells and induce immune escape response, but also interact with other periodontal pathogens to promote the periodontitis. This article summarizes and discusses the research progress on the relationship between Fa and periodontitis in recent years and highlighs a new way to investigate the etiology, prevention and treatment of periodontitis.
3.Study on the value of pharmaceutical service related to risdiplam based on follow-up data of DTP pharmacy
Zaihuan SHI ; Fangting WANG ; Zhijun GUO ; Shuohan HUANG ; Linhui ZHU ; Zheyuan WANG ; Qiong DU ; Qing ZHAI
China Pharmacy 2023;34(19):2414-2418
OBJECTIVE To explore the value of providing pharmaceutical service related to risdiplam in direct-to-patient (DTP) pharmacies. METHODS The follow-up data of spinal muscular atrophy (SMA) patients who purchased and used risdiplam from Shangyao Yunjiankang Yiyao Pharmacy (Shanghai) Co., Ltd. from May 2021 to January 2023 were collected. The medication information, therapeutic efficacy and the occurrence of adverse events were retrospectively analyzed. RESULTS A total of 42 prescriptions were checked by pharmacists in the DTP pharmacies, and 7 prescriptions were found to be unreasonable (16.7%, 7/42), which were corrected after the timely intervention. During the follow-up management, pharmacists replied to 4 patients (9.5%, 4/42) regarding medication consultation about medication requirements and adverse events. Two patients with type Ⅰ SMA experienced adverse events: one of them presented with fever and the other presented with skin dryness with darkening. Both of them were grade Ⅰ toxic reactions and generally did not require clinical treatment. Considering that the patient sustained low-grade fever for a long time, the pharmacist suggested symptomatic treatment under the guidance of the doctor. CONCLUSIONS Pharmacists in DTP pharmacies conducting follow-up management of risdiplam use for rare disease SMA patients can help promote rational, standardized medication for patients.